Announcement PDF Change of Registered Office Address 4 April 2025 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) advises that in accordance with ASX Listing Rule 3.14, that the Company has changed its registered office, effective immediately. The Company’s new contact details are: Registered Office: 29/97 Creek Street, Brisbane City QLD 4000 - ENDS - This announcement has been approved by the Board of Directors. About LTR Pharma LTR Pharma is dedicated to improving men’s health—physically and mentally—through the commercialisation of innovative treatments for erectile dysfunction. The Company’s lead product, SPONTAN®, delivers a PDE5 inhibitor via a fast-acting intranasal spray, enabling onset of action in 10 minutes or less. This unique delivery method offers men greater control, spontaneity, and confidence, distinguishing SPONTAN® from conventional oral therapies. LTR Pharma is focused on building a global footprint, leveraging regulatory milestones, strategic partnerships, and medical community engagement to address unmet patient needs. For further information please contact: Media enquiries Haley Chartres haley@hck.digital Investor enquiries Peter McLennan investors@ltrpharma.com 1800 519 711 | ltrpharma.com | info@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)